
COALITION FOR AFFORDABLE DRUGS V LLC;
HAYMAN CREDES MASTER FUND, L.P.;
HAYMAN ORANGE FUND SPC – PORTFOLIO A;
HAYMAN CAPITAL MASTER FUND, L.P.;
HAYMAN CAPITAL MANAGEMENT, L.P.;
HAYMAN OFFSHORE MANAGEMENT, INC.;
HAYMAN INVESTMENTS, LLC;
NXN PARTNERS, LLC;
IP NAVIGATION GROUP, LLC;
J KYLE BASS; and ERICH SPANGENBERG,
Petitioner,

v.

BIOGEN MA INC.,
Patent Owner.

Case: IPR2016-01993
U.S. Patent No. 8,399,514

DECLARATION OF RICHARD BRUDNICK

II. Background Information 2

III. License Agreement Between Fumapharm AG and Biogen, Inc..... 3

IV. Stock Purchase Agreement Between the Sellers of Fumapharm AG
and Biogen Idec MA Inc. 7

V. Conclusion..... 9

I. Introduction

1. I am the Senior Vice President of Corporate Development & Strategy at Biogen Inc.¹ I have held this position since August 2014.

2. Before my current position, I served as the Vice President of Business Development at Biogen Inc. since October 2011.

3. Between July 2009 and October 2011, I was the Senior Director of Business Development at Biogen Inc. I was also the Senior Director of Business Development at Biogen Inc. between October 2001 and February 2008.

4. I graduated from the Massachusetts Institute of Technology (“MIT”) in 1978 with a bachelor of science degree in management science. I obtained a master’s degree in management science in 1980 from the Sloan School of Management at MIT.

¹ Biogen Inc. was formerly known as Biogen Idec. Inc. and Idec Pharmaceuticals Corp. For simplicity, I refer only to Biogen Inc. in discussing my employment history.

inc., I have led several major transactions, including those relating to Teundia[®], Zinbryta[®], and Sprinraza[®]. I have also negotiated a strategic neurology alliance with Ionis, the formation of a biosimilar joint venture with Samsung (Bioepis), and an Alzheimer's alliance with Eisai.

6. I have participated in many commercial transactions throughout my career. Before joining Biogen Inc., for example, I was the Chief Executive Officer of a regional pharmaceutical distribution business. I helped grow that business to over \$200 million in annual sales before selling it to a strategic buyer. I also co-founded two companies and served as a strategy consultant for Bain & Company.

7. My curriculum vitae is provided as **Exhibit 2023**.

8. All facts in this declaration are based on my personal knowledge unless otherwise stated.

II. Background Information

9. I understand that U.S. Patent No. 8,399,514 ("the '514 patent," **Ex. 1001**) is at issue in this proceeding.

10. I understand that the '514 patent concerns the use of pharmaceutical compositions of certain fumaric acid derivatives (dimethyl fumarate and

derivative is administered in a therapeutically effective dose of about 480 mg/day.

11. I understand that the '514 patent's priority application was filed on February 8, 2007.

12. I understand that Petitioner has cited U.S. Patent No. 7,320,999 ("Joshi '999," **Ex. 1030**) as prior art to the '514 patent. Drs. Joshi and Strebels, the named inventors of Joshi '999, were shareholders of Fumapharm AG.

13. I understand that Joshi '999 claims priority to a German priority application filed on November 19, 1998. (**Ex. 1030** at page 1, pt. (30).)

III. License Agreement Between Fumapharm AG and Biogen, Inc.

14. **Exhibit 2016** is a true and correct copy of a License Agreement between Fumapharm AG and Biogen, Inc.,² which became effective on September 25, 2003.

² The License Agreement identifies Biogen, Inc., a Massachusetts corporation, as "Biogen Inc." (without a comma). I understand that this is a typographical error because to the best of my knowledge no Massachusetts corporate entity named

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.